B. Riley Brokers Boost Earnings Estimates for The Joint Corp. (NASDAQ:JYNT)

The Joint Corp. (NASDAQ:JYNT) – Research analysts at B. Riley boosted their Q3 2024 earnings estimates for Joint in a note issued to investors on Monday, May 6th. B. Riley analyst J. Van. Sinderen now forecasts that the company will post earnings of $0.00 per share for the quarter, up from their prior estimate of ($0.01). B. Riley has a “Buy” rating and a $20.00 price objective on the stock. The consensus estimate for Joint’s current full-year earnings is $0.13 per share. B. Riley also issued estimates for Joint’s Q4 2024 earnings at $0.04 EPS.

Joint (NASDAQ:JYNT) last posted its quarterly earnings data on Thursday, March 7th. The company reported $0.07 EPS for the quarter, topping the consensus estimate of $0.03 by $0.04. The firm had revenue of $30.61 million during the quarter, compared to analyst estimates of $29.63 million. Joint had a negative net margin of 9.24% and a positive return on equity of 3.94%.

Several other research analysts have also issued reports on the company. TheStreet lowered Joint from a “c-” rating to a “d” rating in a research report on Thursday, March 7th. StockNews.com upgraded shares of Joint from a “hold” rating to a “buy” rating in a report on Monday. Finally, Roth Mkm reiterated a “buy” rating and issued a $16.00 target price (up from $13.00) on shares of Joint in a research note on Friday, May 3rd. Two equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat, Joint currently has a consensus rating of “Moderate Buy” and an average price target of $22.00.

Joint Trading Up 2.2 %

Shares of JYNT opened at $16.13 on Tuesday. The firm has a market cap of $240.98 million, a PE ratio of -21.51 and a beta of 1.58. Joint has a 12 month low of $7.31 and a 12 month high of $16.39. The stock has a fifty day moving average price of $12.30 and a 200-day moving average price of $10.27.

Institutional Trading of Joint

Large investors have recently added to or reduced their stakes in the company. Strs Ohio lifted its stake in Joint by 69.1% during the 3rd quarter. Strs Ohio now owns 25,200 shares of the company’s stock valued at $226,000 after acquiring an additional 10,300 shares during the period. Skylands Capital LLC raised its holdings in shares of Joint by 24.5% during the third quarter. Skylands Capital LLC now owns 501,790 shares of the company’s stock worth $4,511,000 after purchasing an additional 98,900 shares during the last quarter. Verus Capital Partners LLC lifted its position in Joint by 24.0% during the third quarter. Verus Capital Partners LLC now owns 108,370 shares of the company’s stock valued at $974,000 after purchasing an additional 20,950 shares during the period. Barclays PLC boosted its holdings in Joint by 29.4% in the third quarter. Barclays PLC now owns 13,725 shares of the company’s stock valued at $123,000 after purchasing an additional 3,119 shares during the last quarter. Finally, Quantbot Technologies LP grew its position in Joint by 345.0% during the 3rd quarter. Quantbot Technologies LP now owns 4,170 shares of the company’s stock worth $37,000 after purchasing an additional 3,233 shares during the period. Hedge funds and other institutional investors own 76.88% of the company’s stock.

Joint Company Profile

The Joint Corp. operates and franchises chiropractic clinics in the United States. The company operates in two segments, Corporate Clinics and Franchise Operations. The Joint Corp. was incorporated in 2010 and is headquartered in Scottsdale, Arizona.